Kala Pharmaceuticals, Inc. (KALA): Price and Financial Metrics

Kala Pharmaceuticals, Inc. (KALA): $14.82

-0.90 (-5.73%)

POWR Rating

Component Grades














  • Growth is the dimension where KALA ranks best; there it ranks ahead of 88.06% of US stocks.
  • The strongest trend for KALA is in Momentum, which has been heading up over the past 135 days.
  • KALA's current lowest rank is in the Stability metric (where it is better than 0.73% of US stocks).

KALA Stock Summary

  • KALA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 1.06% of US stocks.
  • Revenue growth over the past 12 months for KALA PHARMACEUTICALS INC comes in at -65.37%, a number that bests merely 3.04% of the US stocks we're tracking.
  • In terms of volatility of its share price, KALA is more volatile than 99.23% of stocks we're observing.
  • Stocks that are quantitatively similar to KALA, based on their financial statements, market capitalization, and price volatility, are PRTK, CTS, PLAB, POLA, and ASPN.
  • KALA's SEC filings can be seen here. And to visit KALA PHARMACEUTICALS INC's official web site, go to www.kalarx.com.

KALA Valuation Summary

  • KALA's price/sales ratio is 8.1; this is 326.32% higher than that of the median Healthcare stock.
  • Over the past 69 months, KALA's EV/EBIT ratio has gone up 10.8.

Below are key valuation metrics over time for KALA.

Stock Date P/S P/B P/E EV/EBIT
KALA 2023-03-24 8.1 1.7 -0.7 -0.1
KALA 2023-03-23 7.6 1.6 -0.7 -0.1
KALA 2023-03-22 7.4 1.5 -0.6 0.0
KALA 2023-03-21 7.9 1.6 -0.7 -0.1
KALA 2023-03-20 6.6 1.3 -0.6 0.1
KALA 2023-03-17 7.2 1.5 -0.6 0.0

KALA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KALA has a Quality Grade of C, ranking ahead of 25.42% of graded US stocks.
  • KALA's asset turnover comes in at 0.048 -- ranking 323rd of 680 Pharmaceutical Products stocks.
  • AERI, NBY, and FLXN are the stocks whose asset turnover ratios are most correlated with KALA.

The table below shows KALA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.048 0.644 -0.573
2021-03-31 0.037 0.582 -0.486
2020-12-31 0.027 0.501 -0.475
2020-09-30 0.024 0.517 -0.484
2020-06-30 0.022 0.443 -0.584
2020-03-31 0.031 0.632 -0.695

KALA Price Target

For more insight on analysts targets of KALA, see our KALA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.79 Average Broker Recommendation 1.5 (Moderate Buy)

KALA Stock Price Chart Interactive Chart >

Price chart for KALA

KALA Price/Volume Stats

Current price $14.82 52-week high $82.50
Prev. close $15.72 52-week low $3.54
Day low $14.61 Volume 168,300
Day high $16.26 Avg. volume 1,295,287
50-day MA $15.51 Dividend yield N/A
200-day MA $13.95 Market Cap 30.03M

Kala Pharmaceuticals, Inc. (KALA) Company Bio

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.

KALA Latest News Stream

Event/Time News Detail
Loading, please wait...

KALA Latest Social Stream

Loading social stream, please wait...

View Full KALA Social Stream

Latest KALA News From Around the Web

Below are the latest news stories about KALA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate KALA as an investment opportunity.

Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor

ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment of Francis Mah, M.D., as Chief Medical Advisor. In this newly established role, Dr. Mah will provide support for Kala’s clinical development and medical activities and will play a key role in interactions

Yahoo | March 29, 2023

Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe

Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).

Yahoo | March 28, 2023

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

--No safety issues identified in Cohort 1 ---- Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled trial ---- Topline data for Cohort 2 targeted for 1Q 2024; if positive, trial could potentially serve as first of two pivotal trials required to support submission of a BLA -- ARLINGTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceuti

Yahoo | March 27, 2023

Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know

The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | March 24, 2023

Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders

Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.

Yahoo | March 23, 2023

Read More 'KALA' Stories Here

KALA Price Returns

1-mo 46.30%
3-mo -61.15%
6-mo 33.88%
1-year -79.70%
3-year -96.04%
5-year -98.13%
YTD -61.15%
2022 -36.94%
2021 -82.15%
2020 83.74%
2019 -24.54%
2018 -73.55%

Continue Researching KALA

Want to see what other sources are saying about Kala Pharmaceuticals Inc's financials and stock price? Try the links below:

Kala Pharmaceuticals Inc (KALA) Stock Price | Nasdaq
Kala Pharmaceuticals Inc (KALA) Stock Quote, History and News - Yahoo Finance
Kala Pharmaceuticals Inc (KALA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8619 seconds.